THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen (NASDAQ:AMGN) today announced that the European Committee for Medicinal Products for Human Use (CHMP) has requested Amgen and other erythropoiesis-stimulating agent (ESA) marketing authorization holders to participate in a closed meeting of the Scientific Advisory Group on Oncology (SAG-O) on May 15.
